Perfil de la empresa · Healthcare

Zoetis Inc

ZTS · EE. UU.
Bolsa
EE. UU.
País / Región
USA
Fecha de salida a bolsa
1 de febrero de 2013
Empleados
14.500
Precio actual
$78.71
En vivo · 18 de junio de 2026
Compra razonable
≤ $75
Entrada con margen de seguridad
Puntuación de crecimiento Baillie
47/100
Floja
Valor intrínseco · Rango en tres niveles Precio actual $78.71 En vivo · Dentro del rango de valor intrínseco conservador · margen de seguridad significativo

Rango de valoración compuesto · conservador $70–$80 / razonable $100–$120 / optimista $150–$180. A $78.71, Dentro del rango de valor intrínseco conservador · margen de seguridad significativo.

Al publicar $80.23 (28 de mayo de 2026)

Aún no hay análisis sobre este valor en tu idioma.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Capitalización32,39 mil MUS$
Ingresos (TTM)9531 MUS$
EBITDA4074 MUS$
Margen neto28,04 %
ROE67,75 %
PER (TTM)12,67
PER previsto11,6
PEG1,9
BPA6,10 US$
Rentabilidad por dividendo2,56 %
Rango de 52 semanas72,38 US$ – 159,30 US$
Precio objetivo de analistas124,59 US$
Recomendación de analistas4.0 / 5

Datos de EODHD, mostrados en la moneda de reporte; solo a título informativo, no constituye asesoramiento de inversión.

Historia

PróximamenteEsta sección se está completando; vuelve pronto.

Posición en el sector

PróximamenteEsta sección se está completando; vuelve pronto.